BB
CRSP icon

BB Biotech’s CRISPR Therapeutics CRSP Stock Holding History

BB Biotech’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$28.9M Buy
+810,462
New +$28M 0.73% 27

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BB Biotech's CRSP Position: Q1 2019 in Review

BB Biotech opened a new position in CRISPR Therapeutics (CRSP) in Q1 2019: 810,462 shares worth $28.9M. The stake represents 0.73% of the portfolio and ranks #27 among its holdings.

170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

  • BB Biotech held 810,462 shares of CRISPR Therapeutics worth $28.9M as of Q1 2019.
  • CRISPR Therapeutics was a new BB Biotech position in Q1 2019.
  • CRISPR Therapeutics made up 0.73% of BB Biotech's portfolio in Q1 2019, its #27 holding.
  • 170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.